Tongxinluo Capsule for Coronary Microvascular Disease
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of Tongxinluo in patients with microvascular angina
pectoris. Long-term follow-up of 1 to 5 years will be performed to evaluate the effect of
Tongxinluo on long-term adverse cardiovascular events in patients with coronary microvascular
disease.